Pacira BioSciences
PCRX
PCRX
300 hedge funds and large institutions have $3.48B invested in Pacira BioSciences in 2022 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 110 increasing their positions, 95 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
9% more funds holding
Funds holding: 275 → 300 (+25)
2.9% less ownership
Funds ownership: 113.63% → 110.73% (-2.9%)
90% less call options, than puts
Call options by funds: $2.75M | Put options by funds: $26.9M
Holders
300
Holding in Top 10
7
Calls
$2.75M
Puts
$26.9M
Top Buyers
| 1 | +$46.2M | |
| 2 | +$26M | |
| 3 | +$23.3M | |
| 4 |
VOYA Investment Management
Atlanta,
Georgia
|
+$23.2M |
| 5 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
+$19.3M |
Top Sellers
| 1 | -$92M | |
| 2 | -$60.1M | |
| 3 | -$51.5M | |
| 4 |
DM
Deerfield Management
New York
|
-$35.9M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$18M |